{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:52:20Z","timestamp":1793242340546,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Mucous membrane pemphigoid (MMP) is a heterogeneous group of rare, chronic, subepithelial autoimmune blistering diseases (AIBDs) with predominant involvement of mucous membranes that can be sight-threatening and life-threatening. Rituximab (RTX) has demonstrated its efficacy in severe MMP refractory to conventional immunosuppressants in small series that differed in RTX scheme, concomitant therapies, and outcome definitions. In a meta-analysis involving 112 patients with MMP treated with RTX, complete remission (CR) was reported in 70.5% of cases. Herein, we report the largest retrospective monocentric study on RTX efficacy in a series of 109 severe and\/or refractory patients with MMP treated with RTX with a median follow-up period of 51.4 months. RTX was administered in association with immunomodulatory drugs (dapsone, salazopyrine) without any other systemic immunosuppressant in 104 patients. The RTX schedule comprised two injections (1\u00a0g, 2 weeks apart), repeated every 6 months until CR or failure, with a unique consolidation injection (1\u00a0g) after CR. The median survival times to disease control and to CR were 7.1 months and 12.2 months, respectively. The median number of RTX cycles required to achieve CR in 85.3% of patients was two. The larynx was the lesional site that took the longest time to achieve disease control. One year after RTX weaning, CR off RTX was obtained in 68.7% of cases. CR off RTX with only minimum doses of immunomodulatory drugs was achieved in 22.0% of patients. Further, 10.1% of patients were partial responders and 4.6% were non-responders to RTX. Relapse occurred in 38.7% of cases, of whom 91.7% had achieved CR again at the last follow-up. In MMP, CR was achieved in a longer time and after more rituximab cycles than in pemphigus, especially for patients with MMP with anti-type VII collagen reactivity. RTX with concomitant immunomodulatory drugs was not responsible for an unusual proportion of adverse events. This large study confirms that RTX is an effective therapy in patients with severe and\/or refractory MMP, corroborating previous findings regarding the effects of RTX on AIBDs such as pemphigus.<\/jats:p>","DOI":"10.3389\/fimmu.2022.915205","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T13:47:46Z","timestamp":1656596866000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients"],"prefix":"10.3389","volume":"13","author":[{"given":"G\u00e9r\u00f4me","family":"Bohelay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Le Roux-Villet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha\u00ef","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Soued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Shourick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Mellottee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Zumelzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grootenboer-Mignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Gabison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Prost-Squarcioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Musette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.370","article-title":"The First International Consensus on Mucous Membrane Pemphigoid: Definition, Diagnostic Criteria, Pathogenic Factors, Medical Treatment, and Prognostic Indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17395","article-title":"European Guidelines (S3) on Diagnosis and Management of Mucous Membrane Pemphigoid, Initiated by the European Academy of Dermatology and Venereology \u2013 Part Ii","volume":"35","author":"Schmidt","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17397","article-title":"European Guidelines (S3) on Diagnosis and Management of Mucous Membrane Pemphigoid, Initiated by the European Academy of Dermatology and Venereology - Part I","volume":"35","author":"Rashid","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1067\/moe.2003.139","article-title":"Treatment of Severe Erosive Gingival Lesions by Topical Application of Clobetasol Propionate in Custom Trays","volume":"95","author":"Gonzalez-Moles","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2009.06.021","article-title":"Systemic Minocycline as a Therapeutic Option in Predominantly Oral Mucous Membrane Pemphigoid: A Cautionary Report","volume":"38","author":"Carrozzo","year":"2009","journal-title":"Int J Oral Maxillofac Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2010.0847","article-title":"Dapsone Efficacy and Adverse Events in the Management of Mucous Membrane Pemphigoid","volume":"20","author":"Hegarty","year":"2010","journal-title":"Eur J Dermatol"},{"key":"B7","article-title":"Treatment of Cicatricial Pemphigoid With Pulse Intravenous Cyclophosphamide","volume":"137","author":"Musette","year":"2001","journal-title":"Arch Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000168","article-title":"Low-Dose Pulsed Intravenous Cyclophosphamide for Severe Ocular Cicatricial Pemphigoid in Elderly Patients","volume":"33","author":"Friedman","year":"2014","journal-title":"Cornea"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12041","article-title":"Oral Cyclophosphamide Without Corticosteroids to Treat Mucous Membrane Pemphigoid","volume":"168","author":"Munyangango","year":"2013","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for Patients With Refractory Mucous Membrane Pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.056","article-title":"Biologic Treatment Outcomes in Mucous Membrane Pemphigoid: A Systematic Review","author":"Lytvyn","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and Outcome Measures for Mucous Membrane Pemphigoid: Recommendations of an International Panel of Experts","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01030","article-title":"Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients","volume":"9","author":"Gaudin","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.005","article-title":"Comparison of 3 Type VII Collagen (C7) Assays for Serologic Diagnosis of Epidermolysis Bullosa Acquisita (EBA)","volume":"74","author":"Seta","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09566.x","article-title":"Place of Human Amniotic Membrane Immunoblotting in the Diagnosis of Autoimmune Bullous Dermatoses","volume":"162","author":"Grootenboer-Mignot","year":"2010","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(82)34791-0","article-title":"Immunosuppressive Therapy for Progressive Ocular Cicatricial Pemphigoid","volume":"89","author":"Foster","year":"1982","journal-title":"Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjd.16138","article-title":"International Bullous Diseases Group: Consensus on Diagnostic Criteria for Epidermolysis Bullosa Acquisita","volume":"179","author":"Prost-Squarcioni","year":"2018","journal-title":"Br J Dermatol"},{"key":"B18","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.05.002","article-title":"Dancing Partners at the Ball: Rational Selection of Next Generation Anti-CD20 Antibodies for Combination Therapy of Chronic Lymphocytic Leukemia in the Novel Agents Era","volume":"31","author":"Butler","year":"2017","journal-title":"Blood Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh009","article-title":"Mouse CD20 Expression and Function","volume":"16","author":"Uchida","year":"2004","journal-title":"Int Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067752","article-title":"A Single Cycle of Rituximab for the Treatment of Severe Pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First Line Treatment of Pemphigus Vulgaris With a Novel Protocol in Patients With Contraindications to Systemic Corticosteroids and Immunosuppressive Agents: Preliminary Retrospective Study With a Seven Year Follow-Up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-Line Rituximab Combined With Short-Term Prednisone Versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-Group, Open-Label Randomised Trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and Management of Pemphigus: Recommendations of an International Panel of Experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.808536","article-title":"Autoimmune Pemphigus: Latest Advances and Emerging Therapies","volume":"8","author":"Lim","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.020","article-title":"Rituximab Combined With Conventional Therapy Versus Conventional Therapy Alone for the Treatment of Mucous Membrane Pemphigoid (MMP)","volume":"74","author":"Maley","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in Germany","volume":"136","author":"H\u00fcbner","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"721\u2013723","DOI":"10.1016\/j.jaad.2021.11.061","article-title":"Insights Into Clinical and Diagnostic Findings as Well as Treatment Responses in Patients With Mucous Membrane Pemphigoid: A Retrospective Cohort Study","volume":"186","author":"Rashid","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4773","article-title":"Evaluation of Site- and Autoantigen-Specific Characteristics of Mucous Membrane Pemphigoid","volume":"158","author":"van Beek","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2012.119","article-title":"Incidence, Presenting Features, and Diagnosis of Cicatrising Conjunctivitis in the United Kingdom","volume":"26","author":"Radford","year":"2012","journal-title":"Eye (Lond)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20881","article-title":"Clinical Response to Rituximab and Improvement in Quality of Life in Patients With Bullous Pemphigoid and Mucous Membrane Pemphigoid","volume":"186","author":"Rashid","year":"2021","journal-title":"Br J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000231954.08350.52","article-title":"A Prospective Study of Upper Aerodigestive Tract Manifestations of Mucous Membrane Pemphigoid","volume":"85","author":"Alexandre","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20763","article-title":"Laryngeal Mucous Membrane Pemphigoid: A Systematic Review and Pooled-Data Analysis","volume":"120","author":"Higgins","year":"2010","journal-title":"Laryngoscope"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15592","article-title":"Oesophageal Involvement in 26 Consecutive Patients With Mucous Membrane Pemphigoid","volume":"177","author":"Zehou","year":"2017","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14662","article-title":"Laryngeal Mucous Membrane Pemphigoid Serves as a Prognostic Factor for Poor Response to Treatment With Rituximab","volume":"46","author":"Baniel","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.3.264","article-title":"Role of Cyclophosphamide and High Dose Steroid in Ocular Cicatricial Pemphigoid","volume":"79","author":"Elder","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.08.034","article-title":"Pulse IV Cyclophosphamide in Ocular Inflammatory Disease: Efficacy and Short-Term Safety","volume":"111","author":"Durrani","year":"2004","journal-title":"Ophthalmology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13023-018-0823-5","article-title":"Murrell DF. A Review of Scoring Systems for Ocular Involvement in Chronic Cutaneous Bullous Diseases","volume":"13","author":"Lee","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.08.002","article-title":"Treatment of Ocular Mucous Membrane Pemphigoid With Immunosuppressive Drug Therapy","volume":"115","author":"Thorne","year":"2008","journal-title":"Ophthalmology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/imt-2020-0189","article-title":"Clinical and Biological Activity of Rituximab in the Treatment of Pemphigus","volume":"13","author":"Bohelay","year":"2021","journal-title":"Immunotherapy"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.1434","article-title":"Prevalence and Clinical Significance of Anti-Laminin 332 Autoantibodies Detected by a Novel Enzyme-Linked Immunosorbent Assay in Mucous Membrane Pemphigoid","volume":"149","author":"Bernard","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04971-0","article-title":"Anti-Epiligrin Cicatricial Pemphigoid and Relative Risk for Cancer","volume":"357","author":"Egan","year":"2001","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.10.034","article-title":"Incidence and Severity of COVID-19 in Patients With Autoimmune Blistering Skin Diseases: A Nationwide Study","volume":"86","author":"Joly","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00782-x","article-title":"Does Older Age Have an Impact on Rituximab Efficacy and Safety? Results From the NOR-DMARD Register","volume":"37","author":"Mielnik","year":"2020","journal-title":"Drugs Aging"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19890","article-title":"Mortality and Clinical Response of Patients With Bullous Pemphigoid Treated With Rituximab","volume":"185","author":"Yoo","year":"2021","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1038\/s41598-019-40203","article-title":"B-Cell Depletion Induces a Shift in Self Antigen Specific B-Cell Repertoire and Cytokine Pattern in Patients With Bullous Pemphigoid","volume":"9","author":"Berkani","year":"2019","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.915205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T13:47:50Z","timestamp":1656596870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.915205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.915205"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.915205","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"915205"}}